Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) – Drugs In Development, 2021, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family. Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the immune system and close contact with someone who has SARS.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Severe Acute Respiratory Syndrome (SARS) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Severe Acute Respiratory Syndrome (SARS) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 16 and 12 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).- The pipeline guide reviews pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. – The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.- The pipeline guide reviews key companies involved in Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics and enlists all their major and minor projects.- The pipeline guide evaluates Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. – The pipeline guide reviews latest news related to pipeline therapeutics for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Find and recognize significant and varied types of therapeutics under development for Severe Acute Respiratory Syndrome (SARS) (Infectious Disease).- Classify potential new clients or partners in the target demographic.- Develop tactical initiatives by understanding the focus areas of leading companies.- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.- Formulate corrective measures for pipeline projects by understanding Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Adagio Therapeutics Inc

AIkido Pharma Inc

AIM ImmunoTech Inc

AlphaVax Inc

Amide Technologies Inc

Autoimmune Technologies LLC

Biotron Ltd

Cidara Therapeutics Inc

Citospin SL

Cocrystal Pharma Inc

ConserV Bioscience Ltd

CSL Ltd

Fab’entech SA

Global BioLife Inc Ltd

Halo Therapeutics Ltd

Immodulon Therapeutics Ltd

Lattice Biologics Ltd

Merck & Co Inc

Merck KGaA

Novartis AG

Novavax Inc

Oncovir Inc

Pharmazz Inc

Phelix Therapeutics LLC

Pulmotect Inc

Sagimet Biosciences

Sorrento Therapeutics Inc

Starpharma Holdings Ltd

Theravectys SA

Trimunocor Ltd

Valo Therapeutics Oy

VBI Vaccines Inc

Walvax Biotechnology Co Ltd

Table of Contents

Table of Contents

Introduction

Severe Acute Respiratory Syndrome (SARS) - Overview

Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development

Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment

Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development

Severe Acute Respiratory Syndrome (SARS) - Drug Profiles

Severe Acute Respiratory Syndrome (SARS) - Dormant Projects

Severe Acute Respiratory Syndrome (SARS) - Discontinued Products

Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Adagio Therapeutics Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by AIkido Pharma Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by AIM ImmunoTech Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by AlphaVax Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Amide Technologies Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Autoimmune Technologies LLC, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Biotron Ltd, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Cidara Therapeutics Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Citospin SL, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Cocrystal Pharma Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by ConserV Bioscience Ltd, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by CSL Ltd, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Fab’entech SA, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Global BioLife Inc Ltd, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Halo Therapeutics Ltd, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Immodulon Therapeutics Ltd, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Lattice Biologics Ltd, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Merck & Co Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Merck KGaA, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Novartis AG, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Novavax Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Oncovir Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Pharmazz Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Phelix Therapeutics LLC, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Pulmotect Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Sagimet Biosciences, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Sorrento Therapeutics Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Starpharma Holdings Ltd, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Theravectys SA, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Trimunocor Ltd, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Valo Therapeutics Oy, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by VBI Vaccines Inc, 2021

Severe Acute Respiratory Syndrome (SARS) – Pipeline by Walvax Biotechnology Co Ltd, 2021

Severe Acute Respiratory Syndrome (SARS) – Dormant Projects, 2021

Severe Acute Respiratory Syndrome (SARS) – Dormant Projects, 2021 (Contd..1)

List of Figures

List of Figures

Number of Products under Development for Severe Acute Respiratory Syndrome (SARS), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports